Company Market Research Report: BioSig Technologies, Inc.
Company Overview
Name
BioSig Technologies, Inc.
Mission of the Company
BioSig Technologies is on a mission to end reliance on mixed signals and reading between the lines by providing superior signal clarity. They aim to elevate the standard of cardiac care through innovative technology that offers greater clarity and opens doors to better treatment solutions for challenging arrhythmias.
Founded
No information is available on the founding date or founders of the company.
Key People
- Anthony Amato: Chief Executive Officer
- Background in business leadership and entrepreneurial skills. Founded and successfully grew several companies including InQuest Science and Amega Scientific Corporation.
- Ferdinand Groenewald: Interim Chief Financial Officer
- Certified public accountant with extensive experience in finance and accounting.
Headquarters
12424 Wilshire Blvd, Suite 745, Los Angeles, CA 90025, USA
Number of Employees
No information is available regarding the number of employees.
Revenue
No specific revenue information is available.
What is the Company Known For
BioSig Technologies is known for its innovations in medical technology, particularly focused on deciphering the body’s electrical signals to enhance cardiac care through their flagship product, the PURE EP™ Platform.
Products
Overview of Offered Products
- PURE EP™ Platform
- A proprietary technology designed to deliver unprecedented accuracy and precision in intra-cardiac signal visualization for electrophysiology (EP) procedures.
High-Level Description of the Product
The PURE EP™ Platform harnesses a unique combination of hardware and software to accurately capture intracardiac signals with unmatched clarity and precision. It aims to enable physicians to respond to complex cardiac arrhythmias with a highly targeted and insight-based approach.
Key Features of PURE EP™ Platform
1. Algorithmic Noise (AN) Elimination: Removes environmental noise without causing artifacts or signal attenuation.
2. High Frequency Algorithm (HFA): Focuses on signals above 200Hz for clarity and specificity, offering 100% specificity of near field potentials.
3. Automatic Tachycardia Characterization (ATC): Monitors tachycardia rates and conduction patterns in real-time.
4. Near Field Tracking (NFT): Tracks changes in unipolar intracardiac signals, providing visual cues during procedures.
5. Time Efficiency Enhancements: Reduces RF ablation time considerably.
Recent Developments
Business Developments
- Stock Trading Resumption: BioSig Technologies' stock will resume trading on the NASDAQ Capital Market Exchange on October 23, 2024, after successful appeal.
- Asset Acquisition Intent: BioSig announced its intent to acquire assets of Neuro-Kinesis Corporation, aimed at expanding their EP tools.
- Financial Improvements: The company reported a reduction in outstanding payables by $1.5 million during the second quarter of 2024.
New Products and Features
No specific new product launches or features additions noted, outside those described under product updates.
Partnerships
- Entered into a 10-year strategic collaboration with Mayo Clinic in 2017 to enhance clinical features of the PURE EP™ Platform and explore new disease applications under the guidance of Samuel J. Asirvatham, M.D.
Recent Appointments
- Anthony Amato appointed as CEO on April 30, 2024.
- Ferdinand Groenewald named Interim Chief Financial Officer on June 10, 2024.
Other Developments
- BioSig has engaged a consulting firm for business model strategies as of April 4, 2024.
This report is based solely on the data provided and aims to offer a comprehensive overview of BioSig Technologies, Inc., focusing on current and factual details pertaining to company operations, products, and recent developments.
